Ascendis Pharma A/S (ASND) Stock Price
Ascendis Pharma A/S Price
Over the last 13 years Ascendis Pharma A/S grew revenue by 33.9% annually, reaching 808.04 M EUR. For Ascendis Pharma A/S, the net margin of -31.7% is up versus -4,931.6% a few years ago. The consensus 12-month price target for Ascendis Pharma A/S is 285.55 EUR, about 42.3% above where the stock trades today. Of 28 analysts, 27 rate the stock a buy — an overall Buy consensus.
Ascendis Pharma A/S stock price
Ascendis Pharma A/S business model & stock analysis
Frequently asked questions about Ascendis Pharma A/S
The business model of Ascendis Pharma A/S revolves around the development and commercialization of innovative therapies to address unmet medical needs. The company focuses on utilizing its proprietary TransCon technology platform to create prodrug versions of existing drugs that aim to improve their efficacy and therapeutic profile. Ascendis Pharma aims to target rare and serious conditions, particularly in endocrinology and orphan diseases. By combining its deep expertise in medical research and development with strategic partnerships and collaborations, Ascendis Pharma is dedicated to bringing transformative treatment options to patients worldwide.
Ascendis Pharma A/S is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Ascendis Pharma A/S in the market include other pharmaceutical companies such as Novo Nordisk A/S, Amgen Inc., and Eli Lilly and Company. These companies operate in the same healthcare sector and often develop and market similar medical products and treatments. Ascendis Pharma A/S faces competition from these companies in terms of research and development, innovation, and market presence. However, Ascendis Pharma A/S has established itself as a reputable player in the industry through its unique products and differentiated approach in addressing unmet medical needs.
Ascendis Pharma A/S is a reputable biopharmaceutical company headquartered in Denmark. Established in 2006, Ascendis Pharma is dedicated to developing innovative therapies for rare endocrine diseases. The company focuses on utilizing its proprietary TransCon technology platform, which enables the creation of long-acting therapies, to improve patient outcomes. Ascendis Pharma has a strong portfolio of product candidates, including TransCon hGH for growth hormone deficiency and TransCon PTH for hypoparathyroidism. With a commitment to revolutionizing treatment options, Ascendis Pharma continues to make significant strides in the field of endocrinology, enhancing the lives of patients worldwide.
Ascendis Pharma A/S has achieved several significant milestones. The company successfully developed and obtained regulatory approval for their innovative TransCon technology platform. This platform enables the production of long-acting prodrug therapies that offer improved treatment options for patients. Ascendis Pharma A/S also advanced its pipeline of therapeutic candidates, including its lead product, TransCon hGH, for the treatment of growth hormone deficiency. Additionally, the company has formed strategic collaborations with major pharmaceutical companies, further validating their innovative approach. These milestones demonstrate Ascendis Pharma A/S's commitment to advancing medical science and improving patient outcomes.
Ascendis Pharma A/S is primarily present in the United States and Europe, including countries such as Denmark, Germany, and Switzerland.
Ascendis Pharma A/S represents values of innovation, patient focus, and scientific excellence. The company is dedicated to transforming the lives of patients with rare diseases through its cutting-edge technologies and research. Ascendis Pharma takes a patient-centric approach by developing targeted therapies that address unmet medical needs. With a steadfast commitment to scientific rigor, the company aims to advance the understanding and treatment of rare diseases. Ascendis Pharma's corporate philosophy encompasses a culture of collaboration, integrity, and a drive for continuous improvement. By prioritizing the well-being of patients and staying at the forefront of scientific advancements, Ascendis Pharma A/S strives to make a positive impact in the healthcare industry.
Analysts currently set an average price target of 272.45 EUR for the Ascendis Pharma A/S stock (median: 285.55 EUR), implying +35.8 % versus the latest price. The consensus is based on 28 analyst ratings.
28 analysts currently rate the Ascendis Pharma A/S stock: 27 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Ascendis Pharma A/S to generate revenue of 1.35 B EUR and earnings per share of 14.02 EUR.
The Ascendis Pharma A/S share (ASND) is listed on 3 stock exchanges, including: NASDAQ (ASND), Frankfurt (A71.F), München (A71.MU).
Ascendis Pharma A/S is a biopharmaceutical company that focuses on developing innovative therapies for rare diseases. The company's business model is based on utilizing its proprietary TransCon technology platform, which consists of a combination of prodrug and carrier systems to achieve an extended drug profile. The TransCon system allows Ascendis Pharma's products to have a long half-life and controlled release, resulting in increased effectiveness and a better safety profile. The company operates in three main areas: 1. Endocrinology Ascendis Pharma focuses on developing therapies for rare endocrine diseases. The company has a pipeline of several products in various stages of clinical development targeting growth hormone deficiency, hypoparathyroidism, and hypophysitis. The leading product in Ascendis Pharma's endocrinology pipeline is TransCon HGH, a weekly administered growth hormone for individuals with growth hormone deficiency. The product is currently in Phase III of clinical development. 2. Oncology In oncology, Ascendis Pharma focuses on developing therapies for cancer treatment. The company has a pipeline of products in various stages of clinical development targeting solid tumors and hematologic malignancies. The leading product in Ascendis Pharma's oncology pipeline is TransCon PTH, a novel therapy for patients with bone metastasis from breast cancer. The product is currently in Phase I of clinical development. 3. Immunology In the immunology category, Ascendis Pharma focuses on developing therapies for rare immune-related diseases. The pipeline includes products in various stages of clinical development, including primary immunodeficiencies, autoimmune diseases, allergies, and inflammatory diseases. The leading product in Ascendis Pharma's immunology pipeline is TransCon CNP, a novel therapy for patients with vasculitis, an inflammatory disease that affects blood vessels. The product is currently in Phase I of clinical development. Ascendis Pharma has a strong pipeline and is well-positioned to benefit from its TransCon technology platform and grow as a leading provider of innovative therapies for rare diseases. Continuous development of new products is expected to ensure long-term growth within the company.
The expected revenue of Ascendis Pharma A/S is 1.35 B EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Ascendis Pharma A/S is 860.79 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Ascendis Pharma A/S is currently 14.31. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Ascendis Pharma A/S stock.
The price-to-sales ratio (P/S) of Ascendis Pharma A/S is currently 9.13. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Ascendis Pharma A/S stock.
The Eulerpool Quality Score for Ascendis Pharma A/S is 4/10.
The ISIN of Ascendis Pharma A/S is US04351P1012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Ascendis Pharma A/S is A14M6X. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Ascendis Pharma A/S is ASND. The ticker symbol is used to trade Ascendis Pharma A/S shares on the stock exchange.
Ascendis Pharma A/S stock
Ascendis Pharma A/S Peer Group
Ascendis Pharma A/S Ticker
Ascendis Pharma A/S FIGI
All fundamentals and in-depth analysis of Ascendis Pharma A/S
Our stock analysis for Ascendis Pharma A/S stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ascendis Pharma A/S. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.